Table 1. Patient characteristics and response summary.

Subject number /gender/age	Diagnosis/subtypes	Stage of disease at first diagnosis	IPI/aaIPI	The prior therapies	Disease status at study entry	Conditioning therapy	CAR20 kg −1 (×10 7 )	Disease response to CART cells	PFS(m)
UPN01/M/53a	DLBCL/ABC	IIISB	2	R-CHOP×5, R-ESHAP×2	SD	None	0.69	CR	13+
UPN02/M/57b	DLBCL/ABC	IVA	3	R-CHOP×7	PD	CHOP	0.90	PR	6
UPN03/M/25b	DLBCL/ABC	IV/XA	3	CHOP, R-CHOP, R-ICE×3, R-COEP and Auto-HSCT	PD	MACH	0.53	CR	4
UPN04/F/64a	DLBCL/ABC	IIA	3	R-CHOP×6	PD	FC	0.41	PR	2
UPN05/M/36a	DLBCL/ABC	IVA	4	R-CHOP×6, Radiotherapy and R-GDP×3, GDP, DICE×3	PD	EOCH	0.90	SD	2
UPN06/M/44a , c	DLBCL/NOS	IIA	2	CHOP×6, R-CHOP×2, R-ESHAP	SD	CHOD	0.48	PR	(2+11)13+
UPN07/F/46a , d	FL	IVA	3	R-CHOP×5, R-FC	PD	None	0.93	CR	5
UPN08/M/49a , e	MCL	IIIA	3	R-Hyper-CVAD×5	SD	None	1.01	CR	5
UPN09/M/63a , c , d	PCMZL	IVSA	3	R-CHOP×4, DICE	PD	CHODE	1.46	SD	(3+10)13+
UPN10/M/64a	DLBCL/ABC	IIB	3	R-CHOP×2	PR	CHOP	1.29	CR	6+
UPN11/M/70a , f	DLBCL/GCB	IIIXB	3	R-CHOP×5, R-ICE×2, R-ESHAP×2 and Radiotherapy	PR	None	0.47	CR	(16+11)27+

Abbreviations: ABC, activated-B-like-cell; CART, Chimeric Antigen Receptor-modified T cells; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B-cell origin; MCL, mantle cell lymphoma; PCMZL, primary cutaneous marginal zone lymphoma; PD, disease progression; PFS, progression-free survival; PR, partial remission; SD, stable disease.

^aRefractory.

^bRelapsing.

^cUPN06 and UPN09 received local radiotherapy at 2 and 3 months after infusion respectively, then they both got complete remission.

^dBone marrow involvement.

^eLost to follow-up because patient refused to come to appointments.

^fCART-20 infusion again in phase IIa trail after 16-month CR from our phase I trial.

+ indicates an ongoing response as of the time of manuscript submission.